Bid Antibody (BH3 Domain Specific) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P55957 |
---|---|
Clone Names | 2011009 |
Gene ID | 637 |
---|---|
Other Names | BH3-interacting domain death agonist, p22 BID, BID, BH3-interacting domain death agonist p15, p15 BID, BH3-interacting domain death agonist p13, p13 BID, BH3-interacting domain death agonist p11, p11 BID, BID |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP1307a was selected from the region of human Bid BH3 Domain. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | BID |
---|---|
Function | Induces caspases and apoptosis (PubMed:14583606). Counters the protective effect of BCL2 (By similarity). |
Cellular Location | Cytoplasm. Mitochondrion membrane. Mitochondrion outer membrane. Note=When uncleaved, it is predominantly cytoplasmic. [BH3-interacting domain death agonist p13]: Mitochondrion membrane {ECO:0000250|UniProtKB:P70444}. Note=Associated with the mitochondrial membrane. {ECO:0000250|UniProtKB:P70444} [Isoform 3]: Cytoplasm |
Tissue Location | [Isoform 2]: Expressed in spleen, pancreas and placenta (at protein level). [Isoform 4]: Expressed in lung and pancreas (at protein level). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Bid is a death agonist that heterodimerizes with either agonist BAX or antagonist BCL2. Bid is a member of the BCL-2 family of cell death regulators. It is a mediator of mitochondrial damage induced by caspase-8 (CASP8); CASP8 cleaves this encoded protein, and the COOH-terminal part translocates to mitochondria where it triggers cytochrome c release.
References
Wang, X., et al., J. Biol. Chem. 278(31):29184-29191 (2003).Cartron, P.F., et al., Mol. Cell. Biol. 23(13):4701-4712 (2003).Fischer, B., et al., Biochem. Biophys. Res. Commun. 306(2):516-522 (2003).Degli Esposti, M., et al., J. Biol. Chem. 278(18):15749-15757 (2003).Kuwana, T., et al., Cell 111(3):331-342 (2002).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.